Drug-eluting Balloon for Treatment of Non-atherosclerotic Renal Artery Stenosis--a Multicenter Study

NCT ID: NCT05858190

Last Updated: 2023-05-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-01

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will test the efficacy of drug eluting balloon(DEB) for non-atherosclerotic renal artery stenosis. The DEB (paclitaxel eluting balloon) will be used in the intervention group, while the plain old balloon(POB) will be used in the control group. The primary outcome is the effect of blood pressure control.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension, Renovascular

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DEB group

paclitaxel-coated balloon (Orchid, Acotec Scientific Holdings Limited, Beijing, China)

Group Type EXPERIMENTAL

Parallel Assignment

Intervention Type PROCEDURE

intervention group: treated with drug eluting balloon(paclitaxel-coated balloon; Orchid, Acotec Scientific Holdings Limited, Beijing, China); control group :treated with plain old balloon

POB group

Group Type PLACEBO_COMPARATOR

Parallel Assignment

Intervention Type PROCEDURE

intervention group: treated with drug eluting balloon(paclitaxel-coated balloon; Orchid, Acotec Scientific Holdings Limited, Beijing, China); control group :treated with plain old balloon

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Parallel Assignment

intervention group: treated with drug eluting balloon(paclitaxel-coated balloon; Orchid, Acotec Scientific Holdings Limited, Beijing, China); control group :treated with plain old balloon

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age between 18y and 45y.
* with ≥ 60% stenosis in at least one renal artery.
* with hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg).
* patients with no severe renal insufficiency (eGFR\>30 ml/min, length of the kidney ≥ 7cm).
* Good compliance.
* with informed consent.

Exclusion Criteria

* With apparent atherosclerotic risk factors.
* With renal intervention or surgery history.
* With congenital anatomical anomaly.
* With severe renal insufficiency (length of the target kidney \< 7cm, total
* eGFR\<30ml/min, divided eGFR of the target kidney\<8 ml/min)
* With contraindication for antiplatelet therapy.
* With severe cardiopulmonary insufficiency.
* Allergic to contrast medium
* Being pregnant or preparing for pregnancy
* With active cancer.
* Life expectancy \< 12 month
* Without informed consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking Union Medical College Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

xitao song, MD

Role: CONTACT

96-10-69152501

yuexin chen, MD

Role: CONTACT

96-10-69152502

References

Explore related publications, articles, or registry entries linked to this study.

Song X, Fu Y, Lai Z, Di X, Zeng R, Shao J, Ni L, Liu Z, Song X, Ye W, Liu C, Liu B, Zheng Y, Chen Y. Drug-coated balloon for treatment of non-atherosclerotic renal artery stenosis-a multi-center study. BMC Cardiovasc Disord. 2023 Oct 16;23(1):510. doi: 10.1186/s12872-023-03484-5.

Reference Type DERIVED
PMID: 37845604 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HS - 2133

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

AcoArt Ⅰ / SFA China
NCT01850056 COMPLETED NA